Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- ANP.AU
- Price
- -
- Stock movement up
- +0.00 (1.20%)
- Company name
- Antisense Therapeutics Ltd.
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.24%
- 1 year return
- -12.50%
- 3 year return
- -22.43%
- 5 year return
- 13.30%
- 10 year return
- -4.58%
Last updated: 2024-12-17
DIVIDENDS
ANP.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 205.57K |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -11.07M |
| Net income (TTM) | -11.08M |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -5382.97% |
| Profit margin (TTM) | -5392.28% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.23M |
| Net receivables | 1.84M |
| Total current assets | 22.22M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 22.44M |
| Accounts payable | 331.40K |
| Short/Current long term debt | 227.40K |
| Total current liabilities | 1.16M |
| Total liabilities | 1.30M |
| Shareholder's equity | 21.14M |
| Net tangible assets | 21.14M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.56M |
| Capital expenditures (TTM) | 28.60K |
| Free cash flow (TTM) | -8.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ANP.AU | S&P500 | |
| Current price drop from All-time high | -95.82% | -0.60% |
| Highest price drop | -99.15% | -56.47% |
| Date of highest drop | 15 Oct 2018 | 9 Mar 2009 |
| Avg drop from high | -86.66% | -11.12% |
| Avg time to new high | 1698 days | 12 days |
| Max time to new high | 5092 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Employees
0
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found